Weekly TechBio News: Mining Imaging Data
Latest News on Data Mining and Imaging
Hi everyone 👋 and welcome back to another edition of MetaphysicalCells 🛸 on Data Mining, this time regarding Imaging Data (“Weekly TechBio News: Mining Imaging Data”) part of last week’s “Weekly TechBio News I: Data Mining” and “Weekly TechBio News II: Data Mining”, both dedicated to Mining Tools For Omics, Imaging, Patents, Surveys, Medical Records, Electronic Medical Records, Electronic Health Records, Claims Data, Clinical Data and Unpublished Data.
Francis Crick Was Misunderstood
The Central Dogma is not a "dogma," and it has never been broken (
).✴️ Mining Imaging Data
Imaging 👀 is an umbrella term that encompasses bioimaging—refers to technologies for viewing (with microscopy) biological substances that have been fixed/prepared for monitoring—histo-pathology—refers to the examination of a biopsy or surgical specimen by a pathologist—digital pathology—includes the acquisition, management, sharing and interpretation of pathology information including slides—and AI medical imaging—refers to the technique and process of imaging the interior of a body for clinical analysis and medical intervention, as well as visual representation of the function of some organs or tissues (for cardiovascular imaging, breast imaging, lung imaging etc).
This post is about the latest news (in chronological order) of AI imaging companies:
💈 Quibim S.L.
On February 1, 2025, the Spanish startup Quibim Announced $50M in Series A Financing, led by Asabys and Buenavista, to Revolutionize Precision Medicine with AI-Powered Imaging Biomarkers (Series A round of funding). The financing was led by Asabys (through its fund Sabadell Asabys II) and Buenavista Equity Partners (through the BHG I fund, created in partnership with Columbus Venture Partners), and joined by UI Investissements, and GoHub Ventures as new investors. It was also joined by current investors, Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund’s early growth fund), Tony Fadell’s Build Collective, and individual investor Dr. Jonathan Milner, founder of Abcam plc.
Quibim (spun out of La Fe Health Research Institute, part of La Fe Polytechnics and University Hospital in Valencia, Spain) has a cloud-based, tissue-agnostic platform in order to extract key radiomics drivers from the world’s largest imaging data registries (from visual data procured from X-rays, CT scans, and MRIs), developing foundational AI models for medical imaging spanning oncology, immunology, neurology and metabolic disorders (AI-guided precision medicine). On Mar 24 2024, Quibim announced the launch of a new product, QP-Liver, which improves the diagnosis of diffuse liver diseases through highly accurate quantification of tissue fat and iron from MRI scans (CE and UKCA mark for the EU and UK respectively). The company’s flagship product, QP-Prostate, is an advanced AI-driven lesion detection, utilizing biparametric input (T2W and DWI), efficiently identifying prostate cancer lesions, setting a new standard for accuracy, speed and diagnostic precision.
💈 Image Analysis Group (Image Analysis Limited trading as Image Analysis Group, IAG)
On January 29, 2025, Image Analysis Group, a leading imaging Clinical Research Organization (iCRO), announced the release of their award-winning DYNAMIKA V.7, that is the latest version of their cloud-based platform for managing and analyzing imaging data in clinical trials. Following a recent SOC II Type I compliance certification, DYNAMIKA V.7 has achieved the British Standards Institute (BSI) surveillance audit certification (Image Analysis Group Announces Release of DYNAMIKA V.7, their Award-Winning Cloud Platform for Clinical Trial Imaging). Additionally, DYNAMIKA was recently named an Award Category Winner for Innovation in the 2024 Pharmaceutical Technology Excellence Awards, recognizing the platform's proprietary technology and its potential for driving change in the pharmaceutical industry.
The Image Analysis Group (“IAG”) (London UK, 2007) is composed of Image Analysis, Ltd. (HQ: London, UK), Image Analysis, Inc. (HQ: Philadelphia, PA, USA) and Venture Partners. IAG’s foundation is in software development, use of AI and data sciences applied to medical imaging. They offer DYNAMIKA, a cloud platform for robust imaging data management in multi-centre trial setting, that so far has powered over 400 global clinical studies, to manage MRI, CT, X-ray, PET, immunoPET, SPECT, histology and fluoroscopy imaging data.
💈 ThinkCyte Inc
On January 27, 2025, ThinkCyte Introduced New Cell Analysis Platform. In particular, the company announced the pre-commercial launch of its new cell analysis platform, VisionCyte—that leverages high-resolution morphological profiling, high-throughput capabilities and advanced AI analysis to uncover novel biomarkers and facilitate the discovery of new and diversified hits and targets for drug discovery. The company also announced the launch of its Celluminate cell tracking kits, compatible with both VisionSort and VisionCyte, for enabling discovery applications in areas where existing cell surface cell markers are limited such as specific hematological conditions, stem cell research and age-related diseases.
Back in 2024, the Tokyo-based ThinkCyte (2016) announced the commercial launch of VisionSort, an AI enabled technology for characterizing and sorting cells after treatment based on image information at record high-throughput rates by integrating a novel ultrafast imaging technique with AI. In particular, VisionSort is the first cell sorter to combine analytical features found in conventional fluorescence flow sorters with the ability to perform label-free cell sorting and unbiased morphological analysis of cell populations. The combined capabilities can enable researchers to not only view cells based on a combination of known markers and morphological phenotypes, but also sort out unique populations for downstream processing or molecular analysis.
ThinkCyte (with offices in Tokyo, Japan and San Carlos, California and with a $ 3.2M/ JPY 350M seed-financing round in 2018) pioneered the Ghost Cytometry, a proprietary AI-based, label-free cell sorting technology with partners in major global biopharmaceutical companies and leading academic research institutes.
On Jul 1, 2020, Hitachi Ltd (TYO: 6501) and ThinkCyte (CEO: Waichiro Katsuda) announced a collaboration to develop an AI-driven Cell Analysis and Sorting System.
On May 12, 2021, Sysmex Corporation (TYO: 6869) (Kobe, Japan; Chairman and CEO: Hisashi Letsugu) and ThinkCyte, announced the signing of joint development and investment agreements for the commercialization of an AI-based cell analysis technology.
On May 19, 2021, ThinkCyte secured a $26M in Series B Financing. And on Jun 23, 2022, ThinkCyte established its presence in the Bay Area and strengthened the senior management team with industry veterans.
In 2023, Toyoda Gosei Co., Ltd invested in ThinkCyte.
Finally, on January 8, 2024 ThinkCyte announced the launch of its new partnering program for the biopharmaceutical and diagnostics industry, that consists of three strategic arms: the Disease Profiling Platform, Platform, the Biopharma Platform and the AI Platform, each designed to enhance collaboration with industry partners and advance fundamental new discoveries in healthcare.
💈 RadAI (Rad Technologies, Inc)
On January 27, 2025, Rad AI raised $60M in support, boosting the company’s value to $525M in the process (Imaging artificial intelligence firm Rad AI raised $60M, boosts value to $525M). Boston-based growth equity firm Transformation Capital led the Series C funding round, which brings Rad AI’s total raised to over $140M.
RadAI is empowering radiologists with AI to save time, reduce burnout and improve patient care. Founded in 2018 and partnered in 2021, the company so far developed Rad AI Reporting, Rad AI Omni Impressions, Rad AI Nexus and Rad AI Continuity. On January 16, 2024, Rad AI announced a partnership with Google Cloud in scaling its efforts to improve clinical radiologists’ workflows.
💈 PathAI Inc
On January 23, 2025, PathAI announced a strategic partnership with Discovery Life Sciences, a leading biospecimens and specialty lab testing company, to offer Discovery’s customers enhanced, AI-enabled digital and quantitative insights from biospecimens to better inform drug and diagnostic development (PathAI Partners with Discovery Life Sciences to Deploy First AI-Powered Biospecimen Solutions). Through this partnership, Discovery will deploy PathAI’s AISight® Image Management System (IMS), ArtifactDetect and TumorDetect products across its biospecimens business.
Recently (November 21, 2024), PathAI released the PathExplore Fibrosis, an AI-based tool (for research use only and not for use in diagnostic procedures) that analyzes fibrosis and collagen structures from H&E-stained whole-slide tissue images. The software quantifies fibrotic areas and collagen fibers from standard pathology slides, replacing specialized staining techniques and microscopy equipment (PathAI launches AI tool for analyzing fibrosis in cancer tissue samples).
Boston Massachusetts-based PathAI, provides AI-powered research tools and services for digitizing and analyzing pathology images in order to make safer and more affordable the sub-typing of diseases like breast cancer. PathaAI has the pathology market’s first algorithm to use additive multiple instance learning (aMIL)—the AIM-HER2 Breast Cancer—that delivers automated digital HER2 scoring. MIL models enable spatial credit assignment such that the contribution of each region in the image can be exactly computed and visualized, to provide greater transparency for how AI predictions are made.
In April 2023, PathAI and ConcertAI announced a strategic partnership combining PathAI’s PathExplore™ tumor microenvironment panel with ConcertAI’s Patient360™ and RWD360™ products, to launch a first-in-class quantitative histopathology and curated clinical real-world data (RWD) solution. As of 2023, PathAI and Agilent Technologies Inc (NYSE: A) have a strategic partnership to deliver a solution that combines Agilent’s assay development expertise and PathAI’s algorithm development capabilities. By incorporating AI into CDx development, the partnership enables Agilent and PathAI to build integrated solutions with assays and ML analysis algorithms. PathAI works also with Roche Tissue Diagnostics (RTD) to expand digital pathology capabilities for companion diagnostics.
Finally, PathaAI has a multiyear drug discovery partnership with GlaxoSmithKline (LON: GSK) on advancing clinical trials and drug development in oncology and for nonalcoholic steatohepatitis (NASH), an aggressive type of fatty liver disease, by leveraging PathAI’s technologies, including the use of PathAI’s AIM-NASH tool.
💈 JelloX Biotech Inc
On January 22, 2025, JelloX Biotech unveiled its vision for AI and 3D digital pathology to advance patient-centered care (JelloX Aims to Improve Patient-Centered Care with AI-powered 3D Digital Pathology). The vision was first detailed publicly by Dr. Yen-Yin Lin, CEO of JelloX, during the August 2024 Annual Meeting of the Japanese Society of Digital Pathology. JelloX continues to distinguish itself as an early adopter of AI and 3D imaging applied to cancer pathology 👉
"3D pathology can offer at least 50 times more information than conventional 2D methods, providing pathologists with a more comprehensive understanding of a tumor's biology. The power of such a diagnostic tool lies in its ability to help pathologists stratify and personalize, matching the right patients with the right treatment at the right time. This ultimately leads to better prognosis, quality of life, and more patient-centered care", shared Dr. Lin.
Additionally, in July 2024 the Taiwan-based startup JelloX has entered into a collaboration through a know-how agreement with Mayo Clinic, in the US, to further develop and validate their 3D digital imaging and AI analysis technology (Taiwan's startup JelloX Biotech collaborates with Mayo Clinic to enhance AI-based 3D pathology imaging technology).
JelloX Biotech—a Taiwanese startup from National Tsing Hua University—is utilizing 3D digital imaging and AI technology to revolutionize cancer pathology. To be specific, JelloX launched the “JX ACE 3D Pathology Imaging Service” to provide customers a rapid and economic commercialized 3D pathology product most suitable for current pathology diagnosis workflows. In addition to nuclei, membrane and antibody staining signals, this product can detect 3D pathology signatures invisible by conventional 2D methodology. Their patented technologies also include tissue clearing technologies developed for 3D neuron circuit research—and licensed from National Tsing Hua University—and MetaLite which is a cost-effective software platform that employs AI to analyze 3D-rendered thick tissue images quickly, which saves pathologists valuable time while improving diagnostic precision.
💈 Heartflow Inc
On January 22, 2025, HeartFlow partnered with the Boone Heart Institute in Greenwood Village, CO, to launch Gamefilm Registry, a data collection effort to define cardiac risk in retired National Football League (NFL) players (HeartFlow collaborates with Boone Heart Institute). The registry will enroll 120 retired NFL players to assess cardiovascular risks using HeartFlow’s advanced imaging and AI-powered analysis tools, such as its Fractional Flow Reserve-CT (FFR-CT) software, which uses CT scans to calculate how much blood is flowing through the coronary arteries.
Heartflow in California (a leading patent filer in AI-assisted microscopy, for systems determining cardiovascular information of a patient) provides unprecedented visualization of each patient’s coronary arteries, providing a 3D personalized model and analysis, all assisted by AI powered algorithms. Founded in 2010, their HeartFlow FFRCTAnalysis tool for diagnosis and management of coronary artery disease is now commercially available in Europe, US, Canada and Japan. HeartFlow FFRCT is an AI-powered software that maps out the heart’s coronary arteries and any potential blockages through a 3D CT scan. HeartFlow has closed in 2023 $215M in new venture capital funding led by Bain Capital Life Sciences, for a total raised of $792.7M.
💈 Coreline Soft (Coreline Soft Co., Ltd)
On January 8, 2025, Coreline Soft highlighted the clinical results regarding the use of its AVIEW LCS for identifying and assessing pulmonary nodules in lung cancer screening (Coreline Soft highlights clinical results for AVIEW LCS). More specifically, a study published in the European Journal of Cancer included data from the European lung cancer screening project, 4ITLR (4-IN-THE-LUNG-RUN), and demonstrated that AVIEW LCS showed a lower likelihood of misidentifying nodules larger than 100 mm³ compared with human radiologists.
Notably, AVIEW LCS recorded an accuracy rate that was 25% higher than ChestCTExplore by Siemens in alignment with final reading results. This indicates that AVIEW LCS can accurately classify Lung-RADS scores compared to competing products. The results of this paper significantly enhance Coreline Soft's prospects for winning contracts in government-led projects around the world in which they are participating or planning to participate (Coreline Soft's AI technology is superior to the world's No. 1 Siemens... Listed in Nature's sister journal).
Coreline Soft, the AI software developer of AVIEW LCS that analyzes CT scans of the chest based in South Korea, received FDA and Korean Ministry of Food and Drug Safety (MFDS) clearance for its lung cancer detection software, and claims that the software has achieved a sensitivity of 92.3% and a specificity of 80.4% in clinical trials. In August 2023, Coreline Soft, announced it will sell its chest diagnosis solution Aview LCS PLUS—that provides information on the 3 main lung diseases: lung cancer, COPD and coronary artery calcification—in Switzerland through a strategic partnership with the Swiss company HealthCare Connect (HCK).
More news 🗞️
KPMG and Merantix form strategic partnership to move AI forward in Europe
Artificial Intelligence in Medical Imaging Market to Hit
Deepcell Announces Successful Installation of the First Commercial REM-I Platform
Bayer to buy AI imaging platform Blackford Analysis to bolster radiology growth strategy
💈 Brainomix Limited
On November 29, 2024, Brainomix was awarded 🏆 the LSX European Lifestars Award for "Healthtech Company of the Year" by HSBC Innovation Banking, and the "Most Transformative Healthtech Company of the Year" by OBN (Brainomix Awarded for Its Breakthroughs with Transformative AI Imaging Technology).
Brainomix, a spin-out from the University of Oxford in 2010, is an AI-powered MedTech solutions company that has pioneered the development of an AI platform that automates validated imaging biomarkers to improve both diagnosis and treatment decisions. For example, the e-Stroke platform (e-Aspects, e-CTA and e-CTP) is the world's most comprehensive stroke imaging solution, and the e-ILD technology is an automated AI software which has been trained to process high resolution chest CT data in patients with interstitial lung diseases, that cause progressive pulmonary fibrosis. Brainomix is also offering a Cancer solution that has been trained to characterize and quantify solid-tumors using thousands of cases from leading academic institutions, unlocking objective measurements of tumor lengths and other biomarkers such as tumor volume.
💈 Owkin Inc
On November 19, 2024, Owkin and Proscia, a global leader in AI-enabled pathology solutions for precision medicine, announced a strategic partnership to streamline MSI testing (Microsatellite instability, predisposition to mutations) for patients with colorectal cancer (CRC). In particular, the two companies will integrate Owkin’s MSIntuit CRC v2 with Proscia’s Concentriq software platform for studying its impact, and make it available as part of Proscia’s precision medicine AI portfolio to enable laboratories to keep pace with demand for MSI screening (Owkin and Proscia Expand Access to AI Pre-Screening for Colorectal Cancer Patients). The partnership will assist pathologists in the pre-screening of patients with microsatellite stable (MSS)/proficient mismatch repair (pMMR) in colorectal tumors.
A Research Use Only (RUO) version of MSIntuit CRC v2 will soon be available in the US on Proscia’s Concentriq® software platform for studying its impact; further products and solutions will be integrated and accessible in the US and Europe as they are made available
Owkin (2016) is a French-American full-stack AI biotech that identifies novel treatments, optimizes clinical trials and develops diagnostics using histology slides and omics. Owkin is offering solutions for Multimodal patient data, Subgroup discovery, AI drug discovery (BiomarkerPLUS, TargetMATCH and DrugMATCH), AI drug development and AI diagnostics such as: Abstra, Substra, MOSAIC (this is the largest spatial omics atlas to date), MSIntuit™ CRC (a CE-marked AI diagnostic that provides a prescreen approach with digital pathology) and RlapsRisk™ BC (an AI diagnostic to help pathologists and oncologists determine the right treatment pathway for early breast cancer patients).
💈 Onc.AI Inc
On November 06, 2024, Onc.AI announced that results from a study evaluating the use of serial imaging in advanced non-small cell lung cancer (NSCLC) will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting. The multi-institutional study demonstrated improved prediction of overall survival for patients receiving immunotherapy compared to traditional assessment tools (Onc.AI Serial Imaging Response Score Outperforms Traditional Methods for Early Assessment of NSCLC Immunotherapy Outcomes). More specifically, the study showed that using pre-treatment (baseline) and three-month follow-up CT scans to predict overall survival, can serve as a novel way to accurately predict long-term outcomes after a few cycles of treatment.
Onc.AI (US, 2020) is a privately held digital health company on a mission to radically improve oncology decision making. By leveraging a market-leading oncology real-world dataset (diagnostic imaging, EMR, labs, genomics), Onc.AI is developing a pipeline of AI models to fulfill the potential of precision oncology. Their first product will help medical oncologists make treatment decisions for metastatic lung cancer patients treated with PD-1 immunotherapy.
💈 Eyenuk Inc
On October 16, 2024, Eyenuk announced a collaboration with the American Academy of Ophthalmology and its EyeCare America program to provide eye disease screening for underserved communities in Delaware (Eyenuk Teams with the American Academy of Ophthalmology). Under the program, primary care providers in Federally Qualified Health Centers (FQHCs) are using Eyenuk’s EyeArt® AI Eye Screening system to autonomously detect diabetic retinopathy, the leading cause of blindness in working-age adults.
Eyenuk (US, 2010) is a pioneering company in medical AI, that recently gained FDA approval for an innovative technology that analyzes images of the back of your eye and immediately detects if you have some form of diabetic retinopathy. The EyeArt system autonomously analyzes patient's retinal images acquired, using an integrated fundus camera, and robustly detects signs of disease while returns an easy-to-read report in under 60 seconds. EyeArt by incorporating a number of DL and image analysis algorithms automatically assesses the quality of the images, detects the presence and extent of lesions, and determines level of disease based on internationally recognised clinical scales.
💈 Auris Health (Auris Surgical Robotics Inc)
On September 5, 2024, J&J ordered to pay $1B over fallout from Auris robotic surgery deal. Back in 2019 when Johnson & Johnson purchased surgical robot developer Auris Health for $3.4 billion in cash, it also agreed to pay out more—in this case, billions more—if the technology it acquired went on to surpass certain goals. For Auris and its investors, those milestone-based payments put J&J on the hook for up to an extra $2.35 billion.
However, the company’s backers claimed in a years-long lawsuit that the medtech giant was not living up to its end of the bargain, saying it did not devote the resources necessary to help Auris meet the deal’s deadlines. This week, a judge agreed. In Delaware’s Court of Chancery, Vice Chancellor Lori Will said in an opinion that “J&J’s promise to Auris was broken almost immediately after closing” and ordered the company to pay more than $1 billion in damages.
Auris Health engages in the development of robotics technology for medical applications with the MONARCH™ Platform and was acquired in 2019 by Ethicon, part of the Johnson & Johnson Medical Devices Companies. The Monarch Platform, is an endoscopic technology that promises to fight lung cancer by enabling physicians to diagnose hard-to-reach, small peripheral nodules earlier and with greater precision than ever before. The robotic system comprises a Monarch tower, cart, physical controller, and an intuitive physical and digital User Interface that combines traditional endoscopic views with computer-assisted navigation based on 3D models of the patient’s own lung anatomy. The Monarch Platform is an AI system that navigates with 3D models of the patient's lungs and then uploads each case to a cloud.
💈 Alpenglow Biosciences Inc
On August 15, 2024, Alpenglow Biosciences was awarded contracts from Advanced Research Projects Agency for Health (ARPA-H) and the National Institutes of Health (NIH) and secured additional investment to further its clinical product development (Alpenglow Biosciences and Partners Secure a Total of $24M for Development of Alpenglow’s 3D Spatial Pathology Platform). In particular, ARPA-H has awarded Jonathan T.C. Liu, Ph.D., University of Washington Professor and Scientific Co-Founder of Alpenglow Biosciences, a groundbreaking contract to develop a platform technology for precision tumor removal. The five-year ARPA-H contract (up to $21M) is part of the Cancer Moonshot initiative spearheaded by the Biden administration. Alpenglow, alongside elite academic medical centers, is set to transform the fight against cancer with its innovative AI-driven 3D Spatial Biology platform.
Alpenglow Biosciences sheds new light on tissue analysis with an AI-powered 3D approach. With novel chemistry, a patented high-throughput light-sheet microscope and cloud-based AI analysis the company adds a new dimension to your pathology, away from the limitations of conventional 2D, slide-based analysis. Their research services include sample preparation, cloud-based data processing and storage and AI-powered 3D analysis, using its patented multi-resolution 3Di platform for 3D spatial biology.
💈 RetiSpec Inc
On July 26, 2024, RetiSpec Closed $10M USD to Advance Commercialization of its AI-Driven Eye Test for Detection of Alzheimer's Disease. This funding (Series A financing) will enable RetiSpec to accelerate the commercialization of its groundbreaking technology aimed at early detection of Alzheimer's disease. The Series A financing was led by iGan Partners and included new strategic investors, Eli Lilly and Company and Topcon Healthcare, Inc., along with existing investors, Gentex Corporation, the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator, Verge HealthTech Fund, University of Minnesota's Discovery Capital, Ontario Brain Institute, Centre for Aging + Brain Health Innovation, and private investors. This financing brings RetiSpec's total fundraising to $17M USD.
RetiSpec is a Toronto-based medical imaging company that uses AI and a retinal scan to help detect early signs of Alzheimer’s. Initially, their AI-based solution analyzes data-rich images captured with existing retinal imaging cameras available in most eye clinics. The data-rich images of the retina are captured using high resolution retinal imaging providing the basis for detailed analysis and more accurate results. Each pixel has over 100 colors instead of just 3 (i.e., red, green, blue) in a regular color image. Then automated Alzheimer’s detection uses AI to help clinicians detect Alzheimer’s, years before the emergence of clinical symptoms.
🚨 According to Lumea—offering a state-of-the-art Image Management System with industry-leading AI tools from Verily, an Alphabet precision health company, designed to empower diverse histopathology applications—the top 10 companies that have integrated AI in Digital Pathology are:
1️⃣ Aiforia, 2️⃣ AIRA Matrix in India, 3️⃣ Deep Bio in South Korea, 4️⃣ DoMore Diagnostics in Norway, 5️⃣ Indica Labs in UK, 6️⃣ Mindpeak in Germany, 7️⃣ Paige AI in US, 8️⃣ PathAI in US, 9️⃣ Tempus in US and 🔟 Verily an Alphabet company.
💈 Innodem Neurosciences (10032506 Canada Inc)
On March 25, 2024, Innodem Neurosciences announced that its ETNA™-MS has been cleared for commercial use by Health Canada. The Eye Tracking Neurological Assessment for Multiple Sclerosis (ETNA™-MS) is a software as a medical device (SaMD, Class II) intended to administer a non-invasive test and provide an Expanded Disability Status Scale (EDSS) score in the range between 1.0 and 4.5 for use in tracking disease progression in MS patients (INNODEM NEUROSCIENCES' ETNA™-MS OBTAINS HEALTH CANADA'S APPROVAL).
ETNA™-MS turns an iPad Pro into a medical device that can be used in a clinic or at home through patient self-testing. The test, which lasts less than 10 minutes, includes short videos that were designed to highlight eye movement abnormalities as the patient performs several simple eye movement tasks. Then hundreds of eye movement parameters are extracted, combined, and processed by ML algorithms, and ultimately, ETNA™-MS provides an EDSS score (between 1.0 to 4.5) with the potential to improve reproducibility, accuracy, efficiency, access to care and overall convenience.
Innodem Neuroscience—that was founded by Dr. Etienne de Villers-Sidani in 2016, a staff neurologist at the Montreal Neurological Hospital—has an AI eye tracking software technology, capable of capturing and analyzing eye movement biomarkers and gaze mapping biomarkers to assist a clinician's diagnosis and monitor multiple sclerosis (MS) progression.
💈 Aiforia (Also Known As Fimmic, Legal Name Aiforia Technologies)
On January 2, 2024, Aiforia Technologies announced it has entered into an exclusive licensing agreement with the Mayo Clinic in Rochester, MN, to globally commercialize a bespoke AI model to improve prediction of colorectal cancer recurrence (Aiforia Technologies Partner with Mayo Clinic on Colorectal Cancer Recurrence AI). The AI model, which was developed in collaboration with the healthcare giant, identifies important histological features of colorectal cancer and provides a recurrence prediction estimate useful for colorectal cancer treatment decisions.
Aiforia (Helsinki Finland, 2013) by analyzing images uploaded to its cloud is allowing researchers to detect any visible feature or pattern at scale—including in tissues and cells—in order to understand pathophysiology. Aiforia’s platform brings together AI and high-performance cloud computing and assists image-based diagnostics by providing efficient and scalable solutions, enabling new discoveries and clinical support with highly accurate and consistent data. For example with Aiforia Create, Lundbeck pharmaceuticals performed neuroscientific histopathological analysis of alpha-synuclein (a neuronal protein linked to Parkinson’s disease) during preclinical studies, accomplishing high speed and accuracy demonstrating the AI-based quantification was as accurate as the manual method in quantifying α-synuclein.
On June 21, 2021, Epredia—a global precision cancer diagnostics company—announced that it has entered into a distribution agreement for Aiforia's AI based pathology software, in order to distribute Aiforia's portfolio of preclinical and clinical pathology tools globally. In 2022, Aiforia had its fourth CE-IVD marked clinical AI Model for Breast Cancer to its rapidly expanding portfolio of novel tools for cancer diagnostics (Prostate Cancer Gleason, Lung Cancer PD-L1, Breast Cancer PR, ER, Ki-67).
Previous AI Imaging updates:
so interesting! didnt know all of this was possible haha. not really my space but love to see the progress humanity is making